PSMA-targeted Docetaxel Nanoparticles BIND-014

Known as: BIND-014 
A proprietary preparation of polymeric nanoparticles containing the second-generation taxane docetaxel, targeted to prostate-specific membrane… (More)
National Institutes of Health

Related topics

Related topics

1 relation
Microtubule Process

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
Importance Preferential delivery of docetaxel to tumors by prostate-specific membrane antigen (PSMA)-targeted nanoparticles is… (More)
  • table 1
  • table 2
  • figure 2
  • figure 1
  • figure 3
Is this relevant?
2016
2016
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.
PURPOSE First-in-human phase I trial to determine the safety, pharmacokinetics, and antitumor activity of BIND-014, a novel… (More)
Is this relevant?
Review
2014
Review
2014
Targeted therapy using nanotechnology: focus on cancer
Recent advances in nanotechnology and biotechnology have contributed to the development of engineered nanoscale materials as… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
Review
2014
Review
2014
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.
Cancer nanotherapeutics are progressing at a steady rate; research and development in the field has experienced an exponential… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
41 Clinical activity of BIND-014 (docetaxel nanoparticles for injectable suspension) as second-line therapy in patients (pts) with Stage III/IV non-small cell lung cancer
 
Is this relevant?
2013
2013
Abstract LB-203: A phase I study of BIND-014, a PSMA-targeted nanoparticle containing docetaxel, in patients with refractory solid tumors.
 
Is this relevant?
2012
2012
First plant-made biologic approved
The US Food and Drug Administration in May approved Elelyso (taliglucerase alfa), an enzyme produced in genetically engineered… (More)
Is this relevant?
Review
2012
Review
2012
Nanoparticle therapeutics for prostate cancer treatment.
The application of nanotechnology in medicine is offering many exciting possibilities in healthcare. Engineered nanoparticles… (More)
Is this relevant?
2012
2012
Abstract LB-452: A phase I, open label, safety, pharmacokinetic and pharmacodynamic dose escalation study of BIND-014 given by IV infusion to patients with advanced or metastatic cancer
 
Is this relevant?
Review
2011
Review
2011
Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation.
Nanoparticles (NPs) have become an important tool in many industries including healthcare. The use of NPs for drug delivery and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?